Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting β 2-adrenoceptor agonists

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2672-2683

  Sykes, David A ^a   Charlton, Steven J ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Adrenoceptor; Agonist; Association rate (k on); Competition binding; Dissociation rate (k off); Equilibrium; Intrinsic activity; Kinetics

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; FORMOTEROL; INDACATEROL; ISOPRENALINE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING KINETICS; CELL MEMBRANE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLOW RECEPTOR DISSOCIATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; CELL MEMBRANE; CHO CELLS; CRICETINAE; CRICETULUS; DIHYDROALPRENOLOL; HUMANS; IODOCYANOPINDOLOL; KINETICS; RADIOLIGAND ASSAY; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84859059730     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01639.x     Document Type: Article

References (48)

1. 3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists. Proc Natl Acad Sci USA 82: 925-929.
2. Anderson GP, Linden A, Rabe KF (1994). Why are long-acting beta-adrenoceptor agonists long-acting? Eur Respir J 7: 569-578. (Pubitemid 24099018)
3. Battram C, Charlton SJ, Cuenoud B, Dowling MR, Fairhurst RA, Farr D et al. (2006). In vitro and in vivo pharmacological characterization of 5-[(R)2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2- one (Indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 317: 762-770.
4. Beattie D, Bradley M, Brearley A, Charlton SJ, Cuenoud BM, Fairhurst RA et al. (2010). A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators. Bioorg Med Chem Lett 20: 5302-5307.
5. Beeh KM, Beier J (2010). The short, the long and the 'ultra-long': why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther 27: 150-159.
6. Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A (2007). Indacaterol, a novel inhaled {beta}2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 29: 871-878. (Pubitemid 46711890)
7. Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W et al. (2006). Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther 20: 740-749. (Pubitemid 47446351)
8. Bradford MM (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing principle of protein-dye binding. Anal Biochem 72: 248-254.
9. Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S (2007). Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 23: 3113-3122.
10. Carter CM, Leighton-Davies JR, Charlton SJ (2007). Miniaturized receptor binding assays: complications arising from ligand depletion. J Biomol Screen 12: 255-266. (Pubitemid 46364429)
11. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R et al. (2011). Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 337: 600-609.
12. Charlton SJ (2009). Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 158: 165-168. Review.
13. Cheng Y, Prusoff WH (1973). Relationship between inhibition constant (K1) and concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic-reaction. Biochem Pharmacol 22: 3099-3108.
14. Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB et al. (2007). Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med 101: 2065-2075. (Pubitemid 47336870)
15. Coleman RA (2009). On the mechanism of the persistent action of salmeterol: what is the current position? Br J Pharmacol 158: 180-182.
16. Contreras ML, Wolfe BB, Molinoff PB (1986). Kinetic analysis of the interactions of agonists and antagonists with beta adrenergic receptors. J Pharmacol Exp Ther 239: 136-143. (Pubitemid 16006348)
17. Copeland RA, Pompliano DL, Meek TD (2006). Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5: 730-739. (Pubitemid 44323700)
18. De Blasi A, Fratelli M, Marasco O (1988). Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol. Circ Res 63: 273-278.
19. Devanathan S, Yao Z, Salamon Z, Kobilka B, Tollin G (2004). Plasmon-waveguide resonance studies of ligand binding to the human beta 2-adrenergic receptor. Biochemistry 43: 3280-3288. (Pubitemid 38352278)
20. Deyrup MD, Nowicki ST, Richards NG, Otero DH, Harrison JK, Baker SP (1999). Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the beta2-adrenoceptor. Naunyn Schmiedebergs Arch Pharmacol 359: 168-177. (Pubitemid 29142867)
21. Disse B, Speck GA, Rominger KL, Witek TJ Jr, Hammer R (1999). Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 64: 457-464. (Pubitemid 29066693)
22. Doggrell SA (1990). The effects of (+/-)-, (+)- and (-)-celiprolol and bromoacetylalprenololmentane at the beta-adrenoceptors of rat isolated cardiovascular preparations. J Pharm Pharmacol 42: 319-324.
23. Dowling MR, Charlton SJ (2006). Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M-3 receptor. Br J Pharmacol 148: 927-937. (Pubitemid 44543610)
24. Johnson M (1992). Salmeterol: a novel drug for the treatment of asthma. In: Anderson GP, Morley J (eds). New Drugs for Asthma. Birkhauser Verlag: Basel, pp. 79-95.
25. Kanniess F, Cameron R, Owen R, Higgins M (2006). Indacaterol, a novel once-daily beta(2)-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with persistent. J Allergy Clin Immunol 117: S196-S197.
26. Keith RA, Hwang TF, Murthy VS, Kau ST, Salama AI, Giles RE (1989). ICI 147,798: a slowly dissociable beta adrenoceptor antagonist that causes insurmountable beta-1 and surmountable beta-2 adrenoceptor antagonism in isolated tissues. J Pharmacol Exp Ther 248: 240-248. (Pubitemid 19063496)
27. Le Fur G, Paillard JJ, Rougeot C, Uzan A (1980). Tissue levels and displacement of in vivo labelled beta-adrenergic receptors by FM 24, an irreversible or slowly dissociable beta-blocker. Eur J Pharmacol 67: 413-418. (Pubitemid 11241391)
28. Lemoine H (1992). Beta-adrenoceptor ligands - characterization and quantification of drug effects. Quant Struct-Act Rel 11: 211-218.
29. Lucas M, Homburger V, Dolphin A, Bockaert J (1979). In vitro and in vivo kinetic analysis of the interaction of a norbornyl derivative of propranolol with beta-adrenergic receptors of brain and C6 glioma cells; an irreversible or slowly reversible ligand. Mol Pharmacol 15: 588-597. (Pubitemid 9203074)
30. Motulsky HJ, Mahan LC (1984). The kinetics of competitive radioligand binding predicted by the law of mass-action. Mol Pharmacol 25: 1-9. (Pubitemid 14223246)
31. Mueller H, Motulsky HJ, Sklar LA (1988). The potency and kinetics of the beta-adrenergic receptors on human-neutrophils. Mol Pharmacol 34: 347-353.
32. van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP (1996). Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 9: 1684-1688. (Pubitemid 26271155)
33. van Noord JA, Smeets JJ, Maesen FP (1998). A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction. Respir Med 92: 1346-1351. (Pubitemid 29002772)
34. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J (1997). Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 10: 2484-2489. (Pubitemid 28048620)
35. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, Leysen JE (1988). The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 34: 843-851. (Pubitemid 19014407)
36. 2 adrenergic receptor agonists incorporating arylsulfonamide groups. J Med Chem 53: 2280-2288.
37. Rosethorne EM, Turner RJ, Fairhurst RA, Charlton SJ (2010). Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol 382: 255-263.
38. Smith DA, Jones BC, Walker DK (1996). Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16: 243-266. (Pubitemid 26146807)
39. Summerhill S, Stroud T, Nagendra R, Perros-Huguet C, Trevethick M (2008). A cell-based assay to assess the persistence of action of agonists acting at recombinant human beta(2) adrenoceptors. J Pharmacol Toxicol Methods 58: 189-197.
40. Sutherland ER, Brazinsky S, Feldman G, McGinty J, Tomlinson L, Denis-Mize K (2009). Nebulized formoterol effect on bronchodilation and satisfaction in COPD patients compared to QID ipratropium/albuterol MDI. Curr Med Res Opin 25: 653-661.
41. Sykes DA, Dowling MR, Charlton SJ (2009). Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol 76: 543-551.
42. 2-adrenoceptor agonist salmeterol. Br J Pharmacol 158: 183-194.
43. Tashkin DP, Fabbri LM (2010). Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 11: 149.
44. Teschemacher A, Lemoine H (1999). Kinetic analysis of drug-receptor interactions of long-acting beta(2), sympathomimetics in isolated receptor membranes: Evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 288: 1084-1092. (Pubitemid 29254145)
45. Vauquelin G, Charlton SJ (2010). Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488-508.
46. Voss HP, Donnell D, Bast A (1992). Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005. Eur J Pharmacol 227: 403-409.
47. Wegener T, Hedenström H, Melander B (1992). Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 102: 535-538.
48. Weiland GA, Molinoff PB (1981). Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci 27: 313-330. (Pubitemid 12224162)